Chinese investment group Fosun says it has revised an offer for Indian pharmaceutical company Gland Pharma after regulators in India held up the $1.1bn deal during a time of political discord between the two countries.
中國投資集團復星(Fosun)表示，已調整對印度製藥商Gland Pharma的報價，先前印度監管機構在兩國政治不和的背景下叫停了這筆11億美元的交易。
您已閱讀15%（294字），剩餘85%（1650字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。